ACT’s experimental treatment has its origins in a chance discovery that Irina Klimanskaya, the company’s director of stem-cell biology, made while working with embryonic stem cells at Harvard University.
The finding may explain how RNA sequences define the final, folded form of a protein—a fundamental problem in molecular biology, since proteins need to fold in order to function.